Search

Displaying results 3451 - 3460 of 10000 in total
  1. Drug

    AT2220

    go.drugbank.com/drugs/DB05200
    Investigational

    AT2220 is an experimental, oral therapy for the treatment of Pompe disease and belongs to a class of molecules known as pharmacological chaperones. … It is a small molecule designed to act as a pharmacological chaperone that specifically binds, stabilizes, and facilitates the proper folding and trafficking of α-glucosidase (GAA).

  2. Drug

    Orciprenaline

    go.drugbank.com/drugs/DB00816
    Approved

    A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem]

  3. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. … The drug made it to phase III trials before abandoned due to increased stroke.

  4. Drug

    Inotersen

    go.drugbank.com/drugs/DB14713
    ApprovedInvestigational

    Inotersen is a transthyretin-directed antisense oligonucleotide for the treatment of the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. … [L11761] Inotersen has been shown to improve the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis [A39493].

  5. Drug

    4-O-Demethylpenclomedine

    go.drugbank.com/drugs/DB06331
    Experimental

    Synonyms: DM-PEN, 4-Dm-pen
  6. Drug

    Proguanil

    go.drugbank.com/drugs/DB01131
    Approved

    It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite. … Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells.

  7. Drug

    Tonapofylline

    go.drugbank.com/drugs/DB12569
    Investigational

    Tonapofylline has been used in trials studying the treatment of Heart Failure, Renal Insufficiency, and Congestive Heart Failure.

    Categories: Receptor, Adenosine A1
  8. Drug

    NOX-100

    go.drugbank.com/drugs/DB05799
    Investigational

    NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple gas molecule that is a key biological messenger in the body. … NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock.

  9. Drug

    Chlorambucil

    go.drugbank.com/drugs/DB00291
    ApprovedInvestigational

    A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. … Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)

    Synonyms: γ-[p-di(2-chloroethyl)aminophenyl]butyric acid, N,N-di-2-chloroethyl-γ-p-aminophenylbutyric acid
  10. Drug

    Tranilast

    go.drugbank.com/drugs/DB07615
    Investigational

    It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis. … Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma.